Search

Your search keyword '"Tarek M. Okda"' showing total 2 results
Start Over Author "Tarek M. Okda" Topic angiogenesis
2 results on '"Tarek M. Okda"'

1. Design and Optimization of Sesamol Nanosuspensions to Potentiate the Anti-Tumor Activity of Epirubicin against Ehrlich Solid Carcinoma-Bearing Mice

Author

Kholoud A. Elzanaty, Gamal A. Omran, Ehab Kotb Elmahallawy, Ashraf Albrakati, Ayman A. Saleh, Naief Dahran, Alaa S. Alhegaili, Ahmad Salahuddin, Heba Abd-El-Azim, Ahmed Noreldin, and Tarek M. Okda

Subjects
breast cancer, Ehrlich solid tumor, sesamol, Epirubicin, angiogenesis, apoptosis, Pharmacy and materia medica, RS1-441
Abstract

There is a growing interest in discovering natural sources of anti-cancer drugs. Sesamol (SES) is a phenolic compound with antitumor effects. The present study aimed to investigate the anticancer properties of SES and its nano-suspensions (SES-NS) combined with Epirubicin (EPI) in breast cancer (BC) using mice bearing a solid Ehrlich tumor. The study involved 35 female albino mice and investigated the effects of SES and EPI on tumor growth, proliferation, apoptosis, autophagy, angiogenesis, and oxidative stress. Methods including ELISA, qRT-PCR, and immunohistochemistry were utilized. The findings revealed reductions in tumor growth and proliferation using SES either alone or combined and evidenced by decreased AKT (AKT Serine/Threonine kinase1) levels, angiogenesis indicated by lower levels of VEGFR (vascular endothelial growth factor), and apoptosis demonstrated by elevated caspase3 and BAX levels. Furthermore, autophagy increased and was indicated by increased levels of beclin1 and lc3, along with decreased oxidative stress as evidenced by elevated TAC (total antioxidant capacity) and reduced MDA (malondialdehyde) levels. Interestingly, SES-NS demonstrated more significant effects at lower doses. In summary, this study underscores the potential of SES as a promising agent for BC treatment. Moreover, SES-NS potentiated the beneficial effects of EPI while mitigating its adverse effects.

Published
2024
Full Text
View/download PDF

2. Baicalin; a promising chemopreventive agent, enhances the antitumor effect of 5-FU against breast cancer and inhibits tumor growth and angiogenesis in Ehrlich solid tumor

Author

Nisreen H, Shehatta, Tarek M, Okda, Gamal A, Omran, and Mohammad M, Abd-Alhaseeb

Subjects
Flavonoids, Vascular Endothelial Growth Factor A, Pharmacology, Ehrlich solid tumor, Neovascularization, Pathologic, 5-Fluorouracil, Breast Neoplasms, Drug Synergism, Apoptosis, RM1-950, General Medicine, Xenograft Model Antitumor Assays, Tumor Burden, Disease Models, Animal, Mice, Breast cancer, Antineoplastic Combined Chemotherapy Protocols, Animals, Female, Fluorouracil, Baicalin, Angiogenesis, Therapeutics. Pharmacology, Inflammation Mediators
Abstract

Despite considerable advances in cancer treatment, chemotherapy remains a cornerstone in breast cancer therapy. Therefore, reducing chemoresistance and adverse effects of chemotherapy is a priority. In this regard, Baicalin (BA) is the dominant natural flavonoid extracted from the roots of Scutellaria baicalensis showed fascinating antitumor activity in many types of cancers, including breast cancer. The present study aimed to explore the chemopreventive and antitumor action of baicalin alone and in combination with 5-FU in addition to its ability to enhance the antitumor effect of 5-FU on breast cancer using the Ehrlich solid tumor-mice model. Materials and methods: A total of 70 female mice were divided into seven groups (1st group, saline group; 2nd group, DMSO group; 3rd group, BA+EST group; 4th group, EST group; 5th group, EST+5-FU; 6th group, EST+BA group; 7th group, EST+5-FU+BA).tumors were assessed by weight and histopathological examination. Inflammation, angiogenesis, and apoptosis were examined by ELISA, qRT-PCR, and immunohistochemical examinations. Results: showed that pre-treatment with baicalin and treatment with baicalin and/or 5-FU significantly reduced inflammation and angiogenesis indicated by suppression of NF-kB/ IL-1β and VEGF amplification loop with marked elevation in apoptosis indicated by up-regulation of apoptotic caspase-3, pro-apoptotic p53, Bax and downregulation of anti-apoptotic Bcl-2. Conclusion: BA is a promising preventive or adjuvant therapy in breast cancer treatment with 5-FU mainly via cooperative inhibition of inflammation, angiogenesis, and triggering apoptotic cell death.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results